Finance

Lilly taps GLP-1 windfall to fund pipeline as Honeywell trims margins

Eli Lilly is said to pay $3.25 billion upfront for Kelonia Therapeutics, with milestones potentially lifting the deal value to $7 billion, CNBC reports. Honeywell is selling its Productivity Solutions and Services unit for $1.4 billion to Brady Corporation as part of a broader portfolio reshape.

📅 April 20, 2026
⏱️ 2 min read
Lilly taps GLP-1 windfall to fund pipeline as Honeywell trims margins

Key Takeaways

  • Lilly to pay $3.25B upfront for Kelonia, with milestones potentially bringing the deal to $7B
  • Lilly ended 2025 with about $7.3B cash and roughly $9B in free cash flow, enabling aggressive pipeline funding
  • Lilly pursuing acquisitions including Centessa (up to $7.8B), Ventyx (closed at $1.2B), and Orna Therapeutics (up to $2.4B)
  • Honeywell selling PSS unit for $1.4B to Brady Corporation as part of portfolio transformation; WWS may be a future target
  • GLP-1 leadership (Zepbound, Mounjaro) underpins deal activity and obesity/diabetes pricing dynamics

People Involved

  • Jacob Van Naarden Head of Lilly's cancer business

Entities Involved

  • Kelonia Therapeutics Clinical-stage cancer-focused biotech; target of Lilly acquisition
  • Eli Lilly and Company Pharma company pursuing GLP-1-led growth and acquisitions
  • Centessa Pharmaceuticals Potential acquisition target (up to $7.8B)
  • Ventyx Biosciences Acquisition target; deal closed for $1.2B
  • Orna Therapeutics Potential acquisition target (up to $2.4B)
  • Honeywell International Industrial conglomerate selling PSS as part of portfolio reshape
  • Brady Corporation Buyer of PSS unit for $1.4B
  • Warehouse and Workflow Solutions (WWS) Honeywell unit; potential future target in Aerospace/automation context

MarketMoodz Analysis

Lilly’s cash-flow strength and GLP-1 leadership position it to finance a rapid expansion in its pipeline, with Kelonia as a focal point of a broader strategy to diversify beyond core GLP-1 therapies (Zepbound for obesity and Mounjaro for type 2 diabetes). If milestones unlock substantial value, the stock can be supported by an earnings narrative tied to multiple clinical programs, but milestones remain uncertain and depend on regulatory and clinical milestones.

The broader market backdrop includes a pricing-sensitive obesity/diabetes drug space and competitive dynamics within biotech dealmaking. Lilly has shown a pattern of using strong free cash flow to fund high-milestone milestones while attempting to maintain balance-sheet strength; investors should monitor the timing of milestones, regulatory updates on Kelonia, and potential capital allocation effects from Centessa, Ventyx, and Orna deals. Honeywell’s portfolio cleanup echoes a preference for margin-resilient, non-cyclical earnings and could support a more distinct Automation story once Aerospace separation is evaluated.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial